Literature DB >> 2401235

Anabolic effect of human synthetic parathyroid hormone-(1-34) depends on growth hormone.

J M Hock1, J Fonseca.   

Abstract

We tested whether GH is required for the anabolic effect of PTH on bone, using sham-operated (sham) and hypophysectomized (HX) young male rats. HX rats were supplemented daily with 3% sucrose water, T4, and corticosterone. Rats received vehicle or human PTH-(1-34) at 8 micrograms/100 g, sc, once daily, alone or in combination with rat or ovine GH at 0.2 mg/100 g, sc, twice daily or 12 micrograms ovine GH/100 g.day by continuous sc infusion. After 12 days, rats were sedated, and blood, femurs, and tibias were removed. Femur trabecular and cortical bone calcium (Ca), dry weight (DW), and hydroxyproline were measured. PTH increased bone Ca, DW, and hydroxyproline in shams by approximately 30%, but consistently failed to induce an anabolic response in HX rats. GH alone stimulated systemic growth in HX rats and increased their bone Ca and DW by 2-fold. The anabolic effect of PTH was restored in HX rats given both PTH and GH. Total bone mass in these rats was approximately 20% more (P less than 0.05) than the bone mass of rats given GH alone. When food was restricted in shams to limit systemic growth, PTH still induced an increase in bone mass. We conclude that GH or GH-dependent factors, such as insulin-like growth factor-I, which increases in PTH-treated bones in vitro, are required for the anabolic response of bone to PTH in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2401235     DOI: 10.1210/endo-127-4-1804

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

Review 1.  Stemming bone loss by suppressing apoptosis.

Authors:  J M Hock
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

Review 2.  Systemic and local factors and the maintenance of bone quality.

Authors:  E Canalis
Journal:  Calcif Tissue Int       Date:  1993       Impact factor: 4.333

3.  Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study.

Authors:  Adi Cohen; Emily M Stein; Robert R Recker; Joan M Lappe; David W Dempster; Hua Zhou; Serge Cremers; Donald J McMahon; Thomas L Nickolas; Ralph Müller; Alexander Zwahlen; Polly Young; Julie Stubby; Elizabeth Shane
Journal:  J Clin Endocrinol Metab       Date:  2013-03-29       Impact factor: 5.958

4.  In premenopausal women with idiopathic osteoporosis, lower bone formation rate is associated with higher body fat and higher IGF-1.

Authors:  T G Goetz; N Nair; S Shiau; R R Recker; J M Lappe; D W Dempster; H Zhou; B Zhao; X Guo; W Shen; T L Nickolas; M Kamanda-Kosseh; M Bucovsky; J Stubby; E Shane; A Cohen
Journal:  Osteoporos Int       Date:  2021-10-19       Impact factor: 4.507

5.  Osteoclast recruitment and modulation by calcium deficiency, fasting, and calcium supplementation in the rat.

Authors:  K R Wright; P J McMillan
Journal:  Calcif Tissue Int       Date:  1994-01       Impact factor: 4.333

6.  IGF-I induced phosphorylation of PTH receptor enhances osteoblast to osteocyte transition.

Authors:  Tao Qiu; Janet L Crane; Liang Xie; Lingling Xian; Hui Xie; Xu Cao
Journal:  Bone Res       Date:  2018-02-26       Impact factor: 13.567

7.  Age-related increases in parathyroid hormone may be antecedent to both osteoporosis and dementia.

Authors:  Eric R Braverman; Thomas J H Chen; Amanda L C Chen; Vanessa Arcuri; Mallory M Kerner; Anish Bajaj; Javier Carbajal; Dasha Braverman; B William Downs; Kenneth Blum
Journal:  BMC Endocr Disord       Date:  2009-10-13       Impact factor: 2.763

8.  Effect of Transdermal Estradiol and Insulin-like Growth Factor-1 on Bone Endpoints of Young Women With Anorexia Nervosa.

Authors:  Vibha Singhal; Amita Bose; Meghan Slattery; Melanie S Haines; Mark A Goldstein; Nupur Gupta; Kathryn S Brigham; Seda Ebrahimi; Kristin N Javaras; Mary L Bouxsein; Kamryn T Eddy; Karen K Miller; David Schoenfeld; Anne Klibanski; Madhusmita Misra
Journal:  J Clin Endocrinol Metab       Date:  2021-06-16       Impact factor: 5.958

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.